ALG-097558 and Remdesivir
Small molecule
ALG-097558 and Remdesivir is one of 19 small molecule programs targeting COVID-19. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Singulair
AstraZenecaPreclinical
Activella
Eli LillyPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Disease-Modifying Anti-Rheumatic Drugs
RochePreclinical
Pfizer-COVID-19 Vaccine
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALG-097558 and Remdesivir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- UUniversity of Liverpool